Plasminogen (Human) intravenous

BIOLOGICAL2 trials

Sponsors

Prometic Biotherapeutics, Inc.

Conditions

Congenital Plasminogen DeficiencyHypoplasminogenemiaType I Plasminogen Deficiency

Phase 1

A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

CompletedNCT02312180

Prometic Biotherapeutics, Inc.Hypoplasminogenemia, Type I Plasminogen Deficiency

Start: 2014-12-31End: 2016-02-29Updated: 2017-08-29

Phase 2

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

CompletedNCT02690714

Prometic Biotherapeutics, Inc.Congenital Plasminogen Deficiency, Hypoplasminogenemia

Start: 2016-05-04End: 2018-10-08Updated: 2021-08-02

Related Papers

Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes.

2026-07-29

Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy

Haemophilia2025-03-182 citations

Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1

Haemophilia2023-09-0611 citations

Successful Pregnancy in a Patient with Infertility Due to Congenital Plasminogen Deficiency Treated with Intravenous Plasminogen (Human) Replacement Therapy

Blood2020-11-042 citations

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency

Blood2018-01-1045 citations